Zero-shot protein models prioritized HpaBC substitutions, which were experimentally assayed with a L-Dopa-responsive GFP biosensor. EVOLVEpro then combined experimentally validated substitutions, including directed-evolution-derived variants, and selected higher-order designs. The best reported combined variants produced up to 57–58 times the wild-type fluorescence signal under the stated assay conditions. This is a biosensor proxy for L-Dopa production, not a purified-enzyme kinetic measurement; the work also builds on prior directed-evolution mutations and does not establish clinical benefit.
Technology: MutCompute, ProteinMPNN, ESM protein language models and EVOLVEpro combinatorial design
Family ESM / ESMFold: profile · models page
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: 329 model-predicted variants were assayed; 19 showed at least 1.25-fold biosensor signal. EVOLVEpro-selected combined variants yielded up to 57–58-fold normalized fluorescence relative to wild type under the reported assay conditions.
- Still unknown: Fluorescence from a DopA/GFP biosensor is an indirect L-Dopa-production proxy, not a purified-enzyme catalytic constant. The work includes directed-evolution-derived mutations; G295T had prior directed-evolution support. No human therapeutic efficacy is established.
- AI role: MutCompute, ProteinMPNN and ESM prioritized single substitutions for experimental testing; EVOLVEpro combined tested mutations and iteratively selected higher-order variants, including designs incorporating directed-evolution results.
Evidence sources: https://api.biorxiv.org/details/biorxiv/10.64898/2026.07.31.742090 · https://www.biorxiv.org/content/10.64898/2026.07.31.742090v1.full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary bioRxiv v1 API metadata and Crossref posted-date metadata checked; primary v1 full-text indexed extract reviewed for methods, biosensor-normalized outcomes, model role and affiliation. Direct full-text page open was blocked..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
RFdiffusion-based de novo binder design and experimental screening produced synthetic proteins that inhibited three bacterial defense systems: Thoeris and Avs1 in Bacillus subtilis assays, and DdmDE in Vibrio cholerae. Five designed proteins inhibited Thoeris and nine inhibited Avs1 in the reported screens. An engineered SBSphiJ phage carrying both anti-Thoeris and anti-Avs1 proteins replicated in B. subtilis cells expressing both defenses. In native V. cholerae O1 El Tor, two of four tested DdmDE binders improved plasmid resistance to clearance.
Technology: RFdiffusion de novo binder design, ProteinMPNN sequence design and AlphaFold2/3 structure-guided candidate scoring
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: RFdiffusion-based de novo binder design and experimental screening produced synthetic proteins that inhibited three bacterial defense systems: Thoeris and Avs1 in Bacillus subtilis assays, and DdmDE in Vibrio cholerae.
- Still unknown: These are laboratory proof-of-concept results in three bacterial defense systems and specific strains; they do not demonstrate therapeutic phage efficacy in animals or humans. Binder success was low relative to the computationally designed candidate sets, and the authors note that a verified binder may not work against homologous defense proteins. The native V. cholerae result was tested for plasmid retention, not general transformation across clinical isolates. The earlier bioRxiv version is the same study and is not a separate record.
- AI role: RFdiffusion generated candidate binder backbones for selected target sites in the Thoeris, Avs1 and DdmDE defense proteins; ProteinMPNN designed sequences and AlphaFold-based co-folding/scoring prioritized candidates for experiments. The selected synthetic binders were tested for defense inhibition, direct interactions and ability to restore phage infection or plasmid retention. The measured anti-defense functions and engineered-phage outcomes are the paper-specific results enabled by AI-guided protein design.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13402655/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Researchers used computational protein design and generative AI to recode ribosomal proteins in E. coli so they function without isoleucine, then assembled an engineered strain that remained viable and genomically stable over more than 450 laboratory generations. The result shows a reduced amino-acid alphabet can support core translation machinery in this bacterium; the organism still uses isoleucine elsewhere.
Technology: Protein design models including ESM2, MSATr, ProteinMPNN and AfDesign
Family ESM / ESMFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Researchers used computational protein design and generative AI to recode ribosomal proteins in E. coli so they function without isoleucine, then assembled an engineered strain that remained viable and genomically stable over more than 450 laboratory generations.
- Still unknown: This is not a whole 19-amino-acid organism: isoleucine was eliminated from the engineered ribosomal proteins, while the rest of the cell still uses it. Growth was slower than wild type according to the paper.
- AI role: The researchers used AI-guided computational design to propose amino-acid substitutions that allowed selected ribosomal proteins to function after removing isoleucine; the strain was assembled and experimentally tested by the team.
Evidence sources: https://magazine.columbia.edu/article/could-life-be-made-simpler
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: other. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The study combines trRosetta-based scaffold hallucination and Rosetta design with ProteinMPNN/LigandMPNN sequence design and AlphaFold structural filtering to create NTF2-like binders for six small-molecule targets. An optimized cortisol binder had a measured dissociation constant of 68 nM. A purified-protein, split-luciferase cortisol sensor showed an estimated response EC50 of 72 nM; this is a sensor response measurement, not the binding-affinity value or a clinical detection limit. The sensor also responded to cortisone and 17-alpha-hydroxyprogesterone, so specificity needs improvement. The March 2026 peer-reviewed paper is the source of record.
Technology: trRosetta-based hallucination; Rosetta; ProteinMPNN/LigandMPNN sequence design; AlphaFold structural filtering
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Designed binders for six small-molecule targets were measured for binding affinity (nanomolar to low micromolar), and a cortisol binder was used to build a biosensor.
- Still unknown: The abstract states no specific limitations.
- AI role: Deep learning combined with physics-based methods generated a protein family with varied designable pocket geometries.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41467-026-70953-8&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A structure-conditioned workflow combining CycleRFdiffusion, ProteinMPNN and HighFold generated and screened 1,500 cyclic peptide–TREM2 complexes and prioritized four candidates. The lead TP4 showed weak but reproducible TREM2 binding in spectral-shift, microscale-thermophoresis and surface-plasmon-resonance assays. The authors report favorable plasma stability and moderate metabolic stability, presenting the work as an initial proof of concept for TREM2-targeted cyclic binders.
Technology: CycleRFdiffusion backbone design, ProteinMPNN sequence design and HighFold structural prediction/screening
Family RFdiffusion: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The lead TP4 showed weak but reproducible TREM2 binding in spectral-shift, microscale-thermophoresis and surface-plasmon-resonance assays.
- Still unknown: The only reported lead, TP4, is described as a weak binder. The evidence is biophysical binding and stability profiling, not demonstrated modulation of TREM2 signaling, microglial function, disease pathology or therapeutic efficacy. Treat this as proof-of-concept binder discovery.
- AI role: The AI pipeline generated and ranked 1,500 candidate cyclic peptide–TREM2 complexes based on structure, sequence and predicted energetics, from which four were selected for experiments; TP4 was then assessed with multiple orthogonal binding assays.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41435973/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
RFD2-MI designs cysteine-nucleophile proteases that cleave peptide backbones in a sequence-dependent manner. The preprint abstract reports rate enhancements up to 3 × 10^7 and crystal structures close to design models. The journal version reports additional experiments; this draft is bounded to the preprint abstract result and does not transfer later results across versions.
Technology: RFD2-MI; ProteinMPNN; AlphaFold 3
Family ProteinMPNN: profile · models page
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The source reports the study-specific result summarized here.
- Still unknown: Independent replication and broader deployment or clinical benefit are not established by this source review.
- AI role: RFD2-MI generates catalytic protein structures; sequence design and structure prediction support experimental selection.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12668006/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary-source abstract and publication metadata reviewed; full text scope is specified in source_checks..
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
The GRACE workflow combined RFdiffusion structure generation, ProteinMPNN sequence design, CLEAN enzyme classification and solubility/structure filtering to select two carbonic-anhydrase-like sequences from 10,000 candidates. The authors report experimental expression and carbonic anhydrase activity: dCA12_2 at 400 WAU/mL and dCA23_1 at 260 WAU/mL in the reported assay.
Technology: GRACE (RFdiffusion, ProteinMPNN and CLEAN, with computational solubility/structural filters)
Family RFdiffusion: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The authors report experimental expression and carbonic anhydrase activity: dCA12_2 at 400 WAU/mL and dCA23_1 at 260 WAU/mL in the reported assay.
- Still unknown: The reported activity values are from the study's carbonic-anhydrase assay and do not establish purified-enzyme kinetics, physiological CO2-fixation performance, or industrial utility. The designs and validation are a two-protein proof of concept; no independent replication assessed.
- AI role: The generative-design workflow produced structures/sequences and machine-learning function classification prioritized two candidates from a 10,000-sequence pool; researchers expressed both and measured carbonic-anhydrase activity.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11669173/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 89 of works of the same type, year and subfield (OpenAlex work metrics, 20 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A deep-learning pipeline based on inversion of AlphaFold2 and ProteinMPNN designed soluble proteins with claudin, rhomboid-protease and GPCR-like folds. Experiments reported stable, folded soluble designs and structural agreement with target folds. The researchers grafted functional motifs, including a ghrelin-receptor epitope that bound its antibody and active/inactive A2A-receptor-like designs that differed in mini-Gs binding; a binding-site knockout served as a control.
Technology: AF2seq deep-learning backbone design with ProteinMPNN sequence design
Family ProteinMPNN: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Experiments reported stable, folded soluble designs and structural agreement with target folds.
- Still unknown: This is a protein-design proof of concept with in-vitro biophysical and binding assays; the analogues are not native membrane receptors and do not demonstrate signaling, drug activity or therapeutic efficacy. The GPCR analogues tested binding to mini-Gs in conformation-designed constructs. The separate live-catalog record on designed proteins modulating dopamine D1 receptor signaling reports a different binder/target and signaling result; this paper reports soluble receptor-fold analogues and binding assays, not D1 signaling modulation.
- AI role: The deep-learning design pipeline generated soluble analogues of complex membrane-protein folds and the scaffolds into which native functional motifs were grafted. The study tested solubility, thermal stability, structural accuracy and selected binding functions experimentally, including conformation-specific A2A-receptor-like constructs.
Evidence sources: https://www.nature.com/articles/s41586-024-07601-y
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 184 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
CoSaNN combined neural structure prediction, learned sequence optimization and solubility ranking to design variants of an induced-fit ROK carbohydrate kinase. The authors measured expression, thermal stability and activity in vitro. The paper reports measurable expression for 189 of 348 designs in one table, while the strategy-level counts do not sum to that total; no success-rate claim is made here.
Technology: CoSaNN: AlphaFold2-based conformation modeling, ProteinMPNN sequence design and SolvIT graph neural network ranking
Family AlphaFold: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The authors applied CoSaNN to redesign the Arthrobacter polyphosphate glucokinase ROK kinase and performed expression, thermal-stability and enzyme-activity assays on designed variants. The primary Results table reports 189 designs with detectable soluble expression among 348 listed designs; its strategy counts (119+95+94 plus 40 in another strategy; rows in the prose/table are internally inconsistent) do not reconcile cleanly, so the record does not use a single total as a success-rate denominator.
- Still unknown: The study tests a company-designed enzyme set in vitro; it does not establish industrial deployment. The primary paper’s count inconsistency remains explicitly disclosed.
- AI role: CoSaNN uses deep-learning structure prediction (AlphaFold2), sequence optimization with ProteinMPNN and a learned solubility classifier (SolvIT) to rank enzyme designs for experimental characterization.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC10945820/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary PMC full text and PNAS DOI record for CoSaNN-guided glucokinase design, Enzymit affiliations, experimental activity results and the discrepancy in reported design totals..
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Using RFdiffusion and ProteinMPNN, researchers designed proteins that bind helical peptides such as glucagon, neuropeptide Y and parathyroid hormone, with what the authors consider the highest reported affinity for a computer-generated biomolecule. They detect low concentrations of peptides in human serum and withstand heat; a parathyroid-hormone biosensor produced a 21-fold increase in bioluminescence. The press release gives no affinity values.
Technology: RFdiffusion and ProteinMPNN
Family RFdiffusion: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Designed binders were tested in the lab for peptide detection (mass spectrometry, including low-concentration peptide detection) and a bioluminescence biosensor produced a 21-fold signal increase with parathyroid hormone; the press release gives no affinity values.
- Still unknown: The abstract does not describe how affinity was measured, does not mention serum testing, and states no limitations; the press release states no limitations.
- AI role: RFdiffusion, extended for flexible targets and partial diffusion, designed binders to helical peptides, de novo or by refining other designs.
Evidence sources: https://www.ipd.uw.edu/2023/12/ai-generates-proteins-with-exceptional-binding-strengths/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06953-1&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 290 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A neural network generates the amino-acid sequence for a given protein shape in about one second, over 200 times faster than the best previous software, without specialist tuning. A related study shows that proteins designed with ProteinMPNN fold correctly much more often, including nanoscale rings and complex assemblies. Researchers describe it as the beginning of machine learning in protein design.
Technology: ProteinMPNN
Family ProteinMPNN: profile · models page
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Speed is compared with prior software; a related Science study tested lab-made designs, which folded as intended more often, including nanoscale rings imaged by electron microscopy.
- Still unknown: The article gives no quantitative success rates and notes protein data is scarce, requiring trial and error.
- AI role: Neural network generated amino-acid sequences for given protein shapes.
Evidence sources: https://www.ipd.uw.edu/2022/09/proteinmpnn-excels-at-creating-new-proteins/ · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A10.1126/science.add2187&resultType=core&format=json
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 2354 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.